Journal rankings · indicator year 2025
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2025
Pharmaceutical Science journal rankings 2025
43 ranked journals · Subfield in Pharmacology, Toxicology and Pharmaceutics
Pharmaceutical Science has 43 ranked journals in 2025. The median OJR rose 0.06 on 2024 to 0.68, below the world average of 1.00; Q1 starts at OJR 1.30. The highest-scoring journal with a stable rank is Drug Delivery: its likely rank is within the top 3.
Ranks and citation indicators: 2025. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2022–2024, the window the 2025 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Pharmacology, Toxicology and Pharmaceutics (4)
43 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. The small range under it is the likely rank range: in 95% of 1,000 resamples of the journal’s papers, it ranked inside that range. Journals whose ranges overlap are not clearly different. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2024. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2022–2024, the window the 2025 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2022–2024 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2016 to 2025. A label compares the 2022→2025 change with the median change of the journal’s field or domain. Rising needs a relative change of +10% or more that is at least 2 standard errors above zero; Falling needs -9.1% or less (rounded), at least 2 standard errors below zero. Sorting uses that relative change. | Compare |
|---|---|---|---|---|---|---|---|
Rank 1; likely between #1 and #2 of 43Drug DeliveryOATaylor & Francis · United Kingdom | 2.23Q1 | 9.05 0.09 down from 2024 | 415 | 100% | $2,864 | Rising vs field, 2022–25 | |
Rank 2; likely between #1 and #13 of 43Pharmaceutical Science AdvancesOAElsevier BV | 1.90Q1 | 7.02 3.11 up from 2024 | 45 | 100% | $2,000 | ||
Rank 3; likely between #2 and #6 of 43Drug Delivery and Translational ResearchSpringer Science+Business Media · United States | 1.78Q1 | 7.13 1.04 up from 2024 | 631 | 49% | $4,690 | ||
Rank 4; likely between #3 and #8 of 43Expert Opinion on Drug DeliveryTaylor & Francis · United Kingdom | 1.62Q1 | 6.27 0.14 up from 2024 | 337 | 40% | — | Falling vs field, 2022–25 | |
Rank 5; likely between #2 and #11 of 43Future Journal of Pharmaceutical SciencesOASpringer Science+Business Media · Egypt | 1.59Q1 | 5.50 1.44 up from 2024 | 360 | 100% | $0 listed | Rising vs field, 2022–25 | |
Rank 6; likely between #2 and #11 of 43International Journal of Pharmaceutics XOAElsevier BV · Netherlands | 1.56Q1 | 7.14 0.27 up from 2024 | 192 | 100% | $2,590 | ||
Rank 7; likely between #1 and #16 of 43RSC PharmaceuticsOARoyal Society of Chemistry | 1.55Q1 | 6.28no 2024 value | 93 | 100% | — | — | |
Rank 8; likely between #2 and #15 of 43Journal of Pharmaceutical InvestigationSpringer Science+Business Media · South Korea | 1.49Q1 | 5.13 0.84 down from 2024 | 162 | 13% | $3,890 | ||
Rank 9; likely between #5 and #10 of 43International Journal of PharmaceuticsElsevier BV · Netherlands | 1.47Q1 | 6.47 0.70 up from 2024 | 3,167 | 41% | $4,650 | ||
Rank 10; likely between #5 and #12 of 43European Journal of Pharmaceutical SciencesOAElsevier BV · Netherlands | 1.44Q1 | 5.45 0.55 up from 2024 | 744 | 100% | $3,070 | ||
Rank 11; likely between #8 and #14 of 43AAPS PharmSciTechSpringer Science+Business Media · United States | 1.30Q1 | 5.82 1.21 up from 2024 | 767 | 31% | $4,190 | Rising vs field, 2022–25 | |
Rank 12; likely between #8 and #14 of 43European Journal of Pharmaceutics and BiopharmaceuticsElsevier BV · Netherlands | 1.30Q2 | 5.46 0.79 up from 2024 | 787 | 39% | $4,210 | ||
Rank 13; likely between #10 and #15 of 43Pharmaceutical ResearchSpringer Science+Business Media · United States | 1.21Q2 | 4.28 0.35 down from 2024 | 617 | 40% | $4,690 | ||
Rank 14; likely between #12 and #16 of 43Journal of Drug Delivery Science and TechnologyElsevier BV · France | 1.16Q2 | 5.36 0.13 down from 2024 | 3,094 | 21% | $3,810 | ||
Rank 15; likely between #8 and #18 of 43ADMET & DMPKOAInternational Association of Physical Chemists (IAPC) · Croatia | 1.09Q2 | 4.37 0.07 down from 2024 | 106 | 100% | — | ||
Rank 16; likely between #8 and #26 of 43AAPS OpenOASpringer Nature · Germany | 0.93Q2 | 2.12 1.33 down from 2024 | 52 | 100% | $2,090 | ||
Rank 17; likely between #15 and #21 of 43Scientia PharmaceuticaOAÖsterreichische Apotheker-Verlagsgesellschaft m. b. H. · Switzerland | 0.85Q2 | 3.40 0.54 up from 2024 | 190 | 100% | $1,207 | Falling vs field, 2022–25 | |
Rank 18; likely between #15 and #20 of 43Journal of MicroencapsulationTaylor & Francis · United Kingdom | 0.84Q2 | 3.44 0.06 up from 2024 | 144 | 7% | — | Falling vs field, 2022–25 | |
Rank 19; likely between #17 and #24 of 43Therapeutic DeliveryFuture Science Ltd · United Kingdom | 0.73Q2 | 3.22 1.32 up from 2024 | 168 | 90% | — | ||
Rank 20; likely between #17 and #24 of 43Pharmaceutical Development and TechnologyTaylor & Francis · United States | 0.73Q2 | 3.13 0.49 up from 2024 | 279 | 12% | — | ||
Rank 21; likely between #18 and #24 of 43Current Drug DeliveryBentham Science Publishers · Netherlands | 0.71Q2 | 3.16 0.02 up from 2024 | 345 | 8% | — | ||
Rank 22; likely between #19 and #25 of 43Drug Development and Industrial PharmacyTaylor & Francis · United States | 0.68Q2 | 2.76 0.07 up from 2024 | 238 | 8% | — | Falling vs field, 2022–25 | |
Rank 23; likely between #16 and #29 of 43RPS Pharmacy and Pharmacology ReportsOxford University Press | 0.67Q3 | 2.27 0.56 up from 2024 | 74 | 100% | $2,852 | ||
Rank 24; likely between #18 and #30 of 43Critical Reviews in Therapeutic Drug Carrier SystemsBegell House · United States | 0.60Q3 | 3.17 0.31 up from 2024 | 49 | 4% | — | ||
Rank 25; likely between #22 and #27 of 43Journal of Pharmaceutical InnovationSpringer Science+Business Media · United Kingdom | 0.59Q3 | 2.55 0.46 up from 2024 | 288 | 13% | $3,990 | Falling vs field, 2022–25 | |
Rank 26; likely between #23 and #29 of 43Pharmaceutical NanotechnologyBentham Science Publishers · Netherlands | 0.55Q3 | 2.24 0.19 up from 2024 | 206 | 0% | — | Falling vs field, 2022–25 | |
Rank 27; likely between #21 and #34 of 43Assay and Drug Development TechnologiesMary Ann Liebert, Inc. · United States | 0.50Q3 | 2.05 0.11 down from 2024 | 97 | 3% | — | ||
Rank 28; likely between #23 and #33 of 43Recent Advances in Drug Delivery and FormulationNetherlands | 0.48Q3 | 2.02 0.54 up from 2024 | 90 | 2% | — | ||
Rank 29; likely between #25 and #32 of 43Recent Patents on NanotechnologyBentham Science Publishers · Netherlands | 0.47Q3 | 1.95 0.18 up from 2024 | 130 | 8% | — | ||
Rank 30; likely between #25 and #33 of 43Turkish Journal of Pharmaceutical SciencesOAGalenos Yayinevi · Türkiye | 0.47Q3 | 1.09 0.20 down from 2024 | 132 | 100% | — | ||
Rank 31; likely between #27 and #33 of 43International Journal of Pharmacy and Pharmaceutical SciencesOAInnovare Academic Sciences · India | 0.43Q3 | 1.31 0.19 up from 2024 | 269 | 100% | — | Rising vs field, 2022–25 | |
Rank 32; likely between #30 and #34 of 43Brazilian Journal of Pharmaceutical SciencesOAUniversity of São Paulo · Brazil | 0.38Q3 | 1.04 0.17 down from 2024 | 609 | 100% | — | Falling vs field, 2022–25 | |
Rank 33; likely between #29 and #38 of 43Drug Delivery LettersBentham Science Publishers · Netherlands | 0.35Q3 | 1.38 0.49 up from 2024 | 89 | 2% | — | ||
Rank 34; likely between #32 and #36 of 43Indian Journal of Pharmaceutical Education and ResearchAssociation of Pharmaceutical Teachers of India · India | 0.34Q4 | 1.10 0.02 up from 2024 | 710 | 42% | — | ||
Rank 35; likely between #32 and #37 of 43Journal of Fluorine ChemistryElsevier BV · Netherlands | 0.33Q4 | 1.49 0.27 down from 2024 | 278 | 15% | $3,660 | ||
Rank 36; likely between #35 and #39 of 43Journal of Drug Delivery and TherapeuticsOASociety of Pharmaceutical Tecnocrats · India | 0.27Q4 | 0.81 0.06 down from 2024 | 1,009 | 100% | — | ||
Rank 37; likely between #34 and #40 of 43Current NanomedicineNetherlands | 0.27Q4 | 1.25 0.15 up from 2024 | 136 | 0% | — | ||
Rank 38; likely between #36 and #40 of 43Current Drug TherapyBentham Science Publishers · Netherlands | 0.23Q4 | 0.83 0.11 down from 2024 | 261 | 4% | — | ||
Rank 39; likely between #35 and #41 of 43Dissolution TechnologiesUnited States | 0.23Q4 | 0.62 0.05 up from 2024 | 91 | 87% | — | ||
Rank 40; likely between #33 and #41 of 43Journal of Innovations in Applied Pharmaceutical Science (JIAPS)India | 0.19Q4 | 0.62 0.37 up from 2024 | 75 | 100% | — | ||
Rank 41; likely between #38 and #41 of 43Asian Journal of Pharmaceutical Research and DevelopmentOASociety of Pharmaceutical Tecnocrats · India | 0.19Q4 | 0.57 0.04 down from 2024 | 220 | 100% | — | Falling vs field, 2022–25 | |
Rank 42; likely between #42 and #43 of 43Rajiv Gandhi University of Health Sciences Journal of Pharmaceutical SciencesOAIndia | 0.07Q4 | 0.21 0.11 up from 2024 | 85 | 100% | — | ||
Rank 43; likely between #42 and #43 of 43British Journal of PharmacyOAUniversity of Huddersfield Press · United Kingdom | 0.06Q4 | 0.24 0.08 up from 2024 | 113 | — | — |
4 Pharmaceutical Science journals are labelled rising: their OJR moved up between 2022 and 2025 clearly faster than the median journal of their field or domain.
A journal is rising when its OJR grew from 2022 to 2025 faster than the median journal of its field (or domain, when the field is small), by two tests: the relative change is +10% or more, and it is at least 2 standard errors above zero. So the range of the change at 2 standard errors stays above zero, though not necessarily above +10%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the low end of the range, so the surest rises come first.
- 1International Journal of Pharmacy and Pharmaceutical SciencesOAInnovare Academic Sciences · India+113% vs groupOJR 0.20 → 0.43range +69% to +169%
- 2Drug DeliveryOATaylor & Francis · United Kingdom+29% vs groupOJR 1.77 → 2.23range +10% to +50%
- 3AAPS PharmSciTechSpringer Science+Business Media · United States+24% vs groupOJR 1.07 → 1.30range +6.9% to +44%
- 4Future Journal of Pharmaceutical SciencesOASpringer Science+Business Media · Egypt+31% vs groupOJR 1.24 → 1.59range +2.0% to +68%
No-label zone, -9.1% to +10%Group median changeBar scale -65% to +182% (ratio scale)
8 Pharmaceutical Science journals are labelled falling: their OJR moved between 2022 and 2025 clearly behind the median journal of their field or domain.
A journal is falling when its OJR changed from 2022 to 2025 by less than the median journal of its field (or domain, when the field is small), by two tests: the relative change is -9.1% or less (rounded), and it is at least 2 standard errors below zero. So the range of the change at 2 standard errors stays below zero, though not necessarily below -9.1%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the high end of the range, so the surest falls come first.
- 1Drug Development and Industrial PharmacyTaylor & Francis · United States-29% vs groupOJR 0.96 → 0.68range -41% to -14%
- 2Asian Journal of Pharmaceutical Research and DevelopmentOASociety of Pharmaceutical Tecnocrats · India-41% vs groupOJR 0.32 → 0.19range -60% to -11%
- 3Journal of MicroencapsulationTaylor & Francis · United Kingdom-25% vs groupOJR 1.14 → 0.84range -40% to -5.5%
- 4Pharmaceutical NanotechnologyBentham Science Publishers · Netherlands-40% vs groupOJR 0.94 → 0.55range -62% to -5.4%
- 5Scientia PharmaceuticaOAÖsterreichische Apotheker-Verlagsgesellschaft m. b. H. · Switzerland-37% vs groupOJR 1.37 → 0.85range -58% to -5.3%
- 6Expert Opinion on Drug DeliveryTaylor & Francis · United Kingdom-18% vs groupOJR 2.01 → 1.62range -30% to -3.7%
- 7Journal of Pharmaceutical InnovationSpringer Science+Business Media · United Kingdom-21% vs groupOJR 0.76 → 0.59range -37% to -2.1%
- 8Brazilian Journal of Pharmaceutical SciencesOAUniversity of São Paulo · Brazil-25% vs groupOJR 0.51 → 0.38range -43% to -0.8%
No-label zone, -9.1% to +10%Group median changeBar scale -64% to +175% (ratio scale)
Subfields of Pharmacology, Toxicology and Pharmaceutics, with Pharmaceutical Science highlighted.
Journals
The endpoints below each rank show its likely range. How rank ranges are calculated
Citations made in 2025. Corpus-wide, 84.3% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2025. Publication window: 2022–2024. How these summaries are calculated
- Ranked journals
- 43
- Window papers (baseline)
- 20,952 +5.5% from indicator year 2022
- Median OJR
- 0.68 -2.7% from indicator year 2022
- Rising journals (2025)
- 4
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2022–2024 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 13 | 16 | 16 | 16 | 16 | 18 | 19 | 20 | 20 | 22 | 23 | 27 | 31 | 36 | 41 | 43 | 44 | 43 | 43 | 45 | 41 | 42 | 42 | 43 | 42 | 43 | |
| Window papers (baseline) | 7,475 | 7,588 | 7,654 | 8,087 | 8,285 | 8,674 | 8,975 | 9,518 | 10,113 | 10,822 | 11,808 | 12,971 | 14,267 | 15,539 | 16,907 | 17,880 | 18,737 | 18,998 | 18,769 | 18,134 | 17,898 | 18,805 | 19,869 | 20,406 | 20,468 | 20,952 | |
| Median OJR | 0.620 | 0.6911 | 0.623 | 0.85 | 0.826 | 0.77 | 0.81 | 0.89 | 0.82 | 0.91 | 0.828 | 0.880 | 0.879 | 0.72 | 0.6908 | 0.657 | 0.54 | 0.57 | 0.65 | 0.53 | 0.655 | 0.64 | 0.70 | 0.63 | 0.61 | 0.68 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.